Free signup for more
- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Key to changes
?
Text removedfrom 2017 Q2- Text added to 2017 Q3
Content analysis
?Positive | |
Negative | |
Uncertain | |
Constraining | |
Legalese | |
Litigous | |
Readability |
H.S. junior Good
|
Content analysis
?Positive | |
Negative | |
Uncertain | |
Constraining | |
Legalese | |
Litigous | |
Readability |
H.S. sophomore Good
|
New words:
abstract, Aron, contemporaneously, correspondingly, ctDNA, expedite, featuring, fifteen, Knickerbocker, Letter, medium, randomized, Saturday, session, SITC, titled, underway
Removed:
agency, aim, attended, Avastin, beginning, bevacizumab, Boehringer, centrally, correlation, Division, durability, EPO, exciting, Fc, GITR, glycosylation, goal, INBRX, Ingelheim, Inhibrx, Interlocutory, Investigational, ligand, LP, maintained, nintedanib, opened, oppose, opposition, originally, publicly, published, pursued, quantity, seismically, supersede, unsuccessfully
Valuein 2017 Q2 filing- Value in 2017 Q3 filing
Original filings
Filing view